Development of Potent B-RafV600E Inhibitors Containing an Arylsulfonamide Headgroup
Overview
Authors
Affiliations
A potent series of inhibitors against the B-Raf(V600E) kinase have been developed that show excellent activity in cellular assays and good oral bioavailability in rats. The key structural features of the series are an arylsulfonamide headgroup, a thiazole core, and a fluorine ortho to the sulfonamide nitrogen.
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.
Kim Y, Song J, Kim N, Sim T RSC Med Chem. 2025; .
PMID: 39925737 PMC: 11800140. DOI: 10.1039/d4md00881b.
van den Biggelaar R, Walburg K, van den Eeden S, van Doorn C, Meiler E, de Ries A Front Cell Infect Microbiol. 2024; 14:1367938.
PMID: 38590439 PMC: 10999543. DOI: 10.3389/fcimb.2024.1367938.
Structural simplification: an efficient strategy in lead optimization.
Wang S, Dong G, Sheng C Acta Pharm Sin B. 2019; 9(5):880-901.
PMID: 31649841 PMC: 6804494. DOI: 10.1016/j.apsb.2019.05.004.
Tsagris D, Birchall K, Bouloc N, Large J, Merritt A, Smiljanic-Hurley E Bioorg Med Chem Lett. 2018; 28(19):3168-3173.
PMID: 30174152 PMC: 6193536. DOI: 10.1016/j.bmcl.2018.08.028.
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry D, Zuercher W J Pathol. 2016; 239(3):320-34.
PMID: 27102572 PMC: 4922416. DOI: 10.1002/path.4729.